EDIT — Editas Medicine Inc
NASDAQ · Healthcare · Biotechnology
$3.07
+$0.01 (+0.33%)
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ. It is led by Gilmore O'Neill M.D., based in 11 Hurley Street, Cambridge, MA, United States, 02141, with about 87 employees. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Latest reported EDIT revenue for 2025-09-30 was $7.5M. Net income was -$25.1M. Revenue was up 110.8% from 2025-06-30 to 2025-09-30. EDIT currently screens at market cap $375.2M.
Use this EDIT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the EDIT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the EDIT SEC filings page. Lician reads the product cache first so this HTML stays unique to Editas Medicine Inc even when a live quote feed is slow.
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
EDIT Key Statistics
Market Cap
$375.21M
Volume
4.19M
Previous Close
$3.00
Day Range
$3.05 – $3.33
P/B Ratio
81.99
EPS
-$2.88
Revenue
$32.31M
Net Income
-$237.09M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-58.6%
Profit Margin
-733.7%
Employees
87
EDIT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $32.31M | $78.12M | $19.71M | $25.54M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$237.09M | -$153.22M | -$220.43M | -$192.50M |
| EPS (Diluted) | -$2.88 | -$2.02 | -$3.21 | -$2.85 |
Total Assets
$341.59M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$131.54M
Operating Cash Flow
-$210.28M
Free Cash Flow
$0.00
Editas Medicine Inc Company Information
- President, CEO & Director
- Gilmore O'Neill M.D.
- Headquarters
- 11 Hurley Street, Cambridge, MA, United States, 02141
- Website
- www.editasmedicine.com
- Phone
- 617 401 9000
- IPO / Founded
- 2016-02-03
- Sector
- Healthcare
- Industry
- Biotechnology